SG11201907638QA - Proteins binding cd33, nkg2d and cd16 - Google Patents
Proteins binding cd33, nkg2d and cd16Info
- Publication number
- SG11201907638QA SG11201907638QA SG11201907638QA SG11201907638QA SG11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lebanon
- lucent
- pct
- drive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762461145P | 2017-02-20 | 2017-02-20 | |
PCT/US2018/018768 WO2018152516A1 (fr) | 2017-02-20 | 2018-02-20 | Protéines de liaison à cd33, nkg2d et cd16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907638QA true SG11201907638QA (en) | 2019-09-27 |
Family
ID=63169992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907638QA SG11201907638QA (en) | 2017-02-20 | 2018-02-20 | Proteins binding cd33, nkg2d and cd16 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210130471A1 (fr) |
EP (1) | EP3583131A4 (fr) |
JP (2) | JP2020510646A (fr) |
KR (1) | KR20190120775A (fr) |
CN (1) | CN110573530A (fr) |
AU (1) | AU2018220734A1 (fr) |
BR (1) | BR112019017277A2 (fr) |
CA (1) | CA3054078A1 (fr) |
IL (1) | IL268790A (fr) |
MA (1) | MA47508A (fr) |
RU (1) | RU2019129174A (fr) |
SG (1) | SG11201907638QA (fr) |
WO (1) | WO2018152516A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018148445A1 (fr) | 2017-02-08 | 2018-08-16 | Adimab, Llc | Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer |
KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
CA3237846A1 (fr) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Domaines variables d'anticorps ciblant le recepteur nkg2d |
EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
WO2024040195A1 (fr) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditionnement pour l'ingénierie de cellules immunitaires in vivo |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001071005A2 (fr) * | 2000-03-24 | 2001-09-27 | Micromet Ag | Polypeptides multifonctionnnels comportant un site de fixation d'un du complexe recepteur nkg2d |
CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
CN101945893B (zh) * | 2007-12-14 | 2015-02-25 | 诺沃-诺迪斯克有限公司 | 抗人nkg2d抗体及其用途 |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
EP2332994A1 (fr) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Thérapie trispécifique contre la leucémie myéloïde aiguë |
KR102561553B1 (ko) * | 2013-03-15 | 2023-07-31 | 젠코어 인코포레이티드 | 이형이량체 단백질 |
WO2014198748A1 (fr) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticorps à domaine unique anti-her2, polypeptides comportant de tels anticorps et leur utilisation pour le traitement du cancer |
EP2985294A1 (fr) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Molécule d'anticorps de recombinaison et son utilisation pour l'activation des lymphocytes T restreints de cellule cible |
WO2016025880A1 (fr) * | 2014-08-14 | 2016-02-18 | Novartis Ag | Traitement du cancer à l'aide du récepteur d'antigène chimérique gfr alpha-4 |
EP2990416B1 (fr) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Récepteur d'antigène chimérique universel exprimant des cellules immunitaires pour le ciblage de divers antigènes multiples et son procédé de fabrication et son utilisation pour le traitement du cancer, des infections et des troubles auto-immuns |
EP3029137B1 (fr) * | 2014-12-06 | 2019-01-02 | GEMoaB Monoclonals GmbH | Cellules souches pluri-ou multipotentes génétiquement modifiées et leurs utilisations |
EP3307876B1 (fr) * | 2015-06-10 | 2023-09-13 | ImmunityBio, Inc. | Cellules nk-92 modifiées pour traiter le cancer |
CA3016563A1 (fr) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Molecules multispecifiques et multifonctionnelles et leurs utilisations |
WO2018148445A1 (fr) * | 2017-02-08 | 2018-08-16 | Adimab, Llc | Protéines de fixation multi-spécifiques destinées à l'activation de cellules tueuses naturelles et leurs utilisations thérapeutiques pour traiter le cancer |
-
2018
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 BR BR112019017277A patent/BR112019017277A2/pt unknown
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Application Discontinuation
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en active Pending
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/fr active Pending
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/fr active Application Filing
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 AU AU2018220734A patent/AU2018220734A1/en active Pending
- 2018-02-20 CA CA3054078A patent/CA3054078A1/fr active Pending
- 2018-02-20 RU RU2019129174A patent/RU2019129174A/ru unknown
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
-
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
-
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL268790A (en) | 2019-10-31 |
KR20190120775A (ko) | 2019-10-24 |
WO2018152516A1 (fr) | 2018-08-23 |
AU2018220734A1 (en) | 2019-09-12 |
JP2023052214A (ja) | 2023-04-11 |
BR112019017277A2 (pt) | 2020-04-14 |
MA47508A (fr) | 2021-03-17 |
RU2019129174A3 (fr) | 2021-07-02 |
EP3583131A4 (fr) | 2021-03-17 |
CA3054078A1 (fr) | 2018-08-23 |
CN110573530A (zh) | 2019-12-13 |
JP2020510646A (ja) | 2020-04-09 |
EP3583131A1 (fr) | 2019-12-25 |
US20210130471A1 (en) | 2021-05-06 |
RU2019129174A (ru) | 2021-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
SG11201907271PA (en) | Proteins binding psma, nkg2d and cd16 | |
SG11201907648XA (en) | Proteins binding gd2, nkg2d and cd16 | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
CA3015496A1 (fr) | Commande vocale d'un systeme de lecture multimedia | |
SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
SG11201907645PA (en) | Proteins binding cd123, nkg2d and cd16 | |
SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201900501RA (en) | Cannabis composition | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains |